Synonyms: AZ-7371 | compound 1 [PMID:24957839] | TBA7371
Compound class:
Synthetic organic
Comment: TBA-7371 was identified in a lead optimization study of a series of 1,4-azaindoles, a novel class of antibacterial compounds [1-3]. It has potent antimycobacterial activity and is under clinical evaluation as a treatment for tuberculosis (TB). TBA-7371 is a non-covalent inhibitor of decaprenylphosphoryl-beta-D-ribose oxidase (DprE1), an essential mycobacterial cell wall biosynthesis enzyme [1].
|
|
No information available. |
Summary of Clinical Use ![]() |
TBA-7371 has completed a Phase 2 trial to evaluate safety, pharmacokinetics, and early bactericidal activity (EBA) in adult participants with rifampicin-sensitive pulmonary tuberculosis (NCT04176250). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03199339 | A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371 | Phase 1 Interventional | Global Alliance for TB Drug Development | ||
NCT04176250 | Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis | Phase 2 Interventional | Bill & Melinda Gates Medical Research Institute |